Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Rhabdomyosarcoma 1Neoplasms 1Myelodysplastic Syndromes 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Fanconi Anemia 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Fluorodeoxyglucose F18 7Irinotecan 4Fluorouracil 4Cyclophosphamide 4Bevacizumab 4toripalimab 3pembrolizumab 3olaparib 3Radiosurgery 3Cisplatin 3Capecitabine 3vistusertib 2tislelizumab 2spartalizumab 2fludarabine 2atezolizumab 2apatinib 2Temozolomide 2Technetium 2Specimen Handling 2Sirolimus 2Radiotherapy 2Proton Therapy 2Paclitaxel 2Leucovorin 2Letrozole 2Hydroxychloroquine 2Everolimus 2Drug Therapy 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumor × prexasertib × Clear all
NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
29 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡